August 12, 2020

The Niche

Knoepfler lab stem cell blog


2 min read

We just ran a CRISPR backronym contest here at the Niche blog. What were we looking for in terms of CRISPR backronyms? We were hoping to see backronyms that were in a sense clever explanations using the letters C, R, I, S, P, R for what CRISPR might “really” stand for if it weren’t Clustered, Regularly, Interspace…you know, the official meaning. We received 58 entries, which were evaluated by the judges: Ben Zimmer, Antonio Regalado, and I. We each scored them separately and then added …Read More

2 min read

Update: you can also enter our contest on Twitter using the hashtag #CRISPRback. Do you like contests, words, science, and cash? Enter our new contest. It’s a backronym contest for CRISPR. The author of the best backronym will win a $50 prize paid by me and fame of course as the winner. The judges will be WSJ columnist Ben Zimmer, Senior Editor at MIT Tech Review Antonio Regalado, and myself. A backronym is like an acronym, but flipped around in the sense that you choose words …Read More

2 min read

It wasn’t so long ago that I did a post explaining why after following the company for years, I finally bought a small amount of stock in the stem cell biotech, Advanced Cell Technology (ACT; symbol ACTC). In part it was motivated by my enthusiasm to see them publishing a paper, a very preliminary paper, on their human ES cell-based clinical trials for macular degeneration. However, being more of a scientist than a stock trader, I found myself fairly quickly having second thoughts, particularly …Read More